Abstract
ObjectivesIn the present study, we sought to investigate the association between red cell distribution width (RDW) and stroke severity and outcome in patients who underwent anti-thrombolytic therapy with tissue plasminogen activator (tPA).ResultsIn this prospective study, 282 stroke patients who underwent tPA injection were included. The categorization of RDW to < 12.9% and > 13% values revealed insignificant difference in stroke severity score, accounting for the mean 36-h NIHSS of 8.19 ± 8.2 in normal RDW values and 9.94 ± 8.28in higher RDW group (p = 0.64). In seventh day, NIHSS was 6.46 ± 7.28 in normal RDW group and was 8.52 ± 8.35 in increased RDW group (p = 0.058). Neither the 36-h, nor the seventh day and 3-month mRS demonstrated significant difference between those with normal and higher RDW values.
Highlights
Cerebral ischemic attack is a general term used for ischemic stroke, including cerebral thrombosis, embolism, and lacunar infarction
Seventy percent of cerebrovascular attacks are related to ischemic stroke, which is induced by a disorder in the brain–blood supply lesions
Feng et al suggested that increased inflammation and oxidative stress during ischemia result in elevation in red cell distribution width (RDW) and are associated with poor prognosis
Summary
Cerebral ischemic attack is a general term used for ischemic stroke, including cerebral thrombosis, embolism, and lacunar infarction. Seventy percent of cerebrovascular attacks are related to ischemic stroke, which is induced by a disorder in the brain–blood supply lesions. Tissue plasminogen activator (tPA) antithrombotic therapy, a recently introduced treatment for ischemic stroke, has had promising results [3, 4]. A predictive parameter for stroke severity would enhance the antithrombotic therapeutic approach, which. Different studies have shown an increased value of RDW after ischemic stroke [14,15,16,17,18]. It is still unclear that if RDW can predict the treatment response in stroke patients who are receiving antithrombotic therapy [16].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
